VivoSeq
Ophthalmology

Retinopathy of Prematurity

35

Pipeline Programs↗

7

Active Trials↗

18

Companies Involved↗

Retinopathy of Prematurity is a moderately active landscape with 35 programs across 18 companies. The most active players are Sanofi, Takeda, Kaken Pharmaceutical. 7 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

91/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1Takeda logo

Takeda

2 programs

Phase 2K

Kaken Pharmaceutical

1 program

Phase 2J

Javelin Pharmaceuticals

1 program

Phase 2I

INSYS Therapeutics Inc

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical5

Ferrous Sulfate

Auerbach Hematology Oncology Associates P C

Paracetamol

GSK

Conbercept

Chengdu Kanghong Biotech Co., Ltd.

Dexamethasone Eyedrop

Region Skane

Intravitreal Injection of Ranibizumab

University of Sao Paulo

Phase 13

Standard Mydrin-P

The University of Hong Kong

Microdrop Mydrin-P

The University of Hong Kong

Betaxolol

Sanofi

Phase 29

Caffeine Citrate

Kaken Pharmaceutical

Ketorolac

Javelin Pharmaceuticals

Fentanyl Citrate

INSYS Therapeutics Inc

Propranolol

Wyeth-Lederle Vaccines

Rhigf-I/rhigfbp-3

Takeda

Phase 311

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Bevacizumab

Bio-Thera Solutions

Aflibercept

Regeneron

Ranibizumab

Roche

Receive Artificial Tears Drop

Shahid Beheshti University of Medical Sciences

Approved7

Propofol

Fresenius Kabi Oncology Ltd.

Ketamine

Aultman Health Foundation

Dexamethasone

Aspen Global Incorporated

Ibuprofen

Kenvue Brands

Sevoflurane

AbbVie

Analysis

Modality Breakdown

86%

Small molecule

37 of 43 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody49%Protein / enzyme25%

Small molecule leads; the ring shows all 43 classified programs, each share of the total. Modality classified for 100% of 49 pipeline programs.

Analysis

Trial Status

48

clinical trials

Completed30 · 63%
Unknown status7 · 15%
Recruiting6 · 13%
Terminated2 · 4%
No longer available1 · 2%
Withdrawn1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

48 trials

Intranasal Dexmedetomidine for Pain Management During Screening for Retinopathy of Prematurity
Recruiting·—·Phase 3·NCT06067958·30 enrolled
Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity
Recruiting·UUniversity of Zurich·Phase 2·NCT03083431·276 enrolled
Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
Recruiting·—·N/A·NCT06717412·146 enrolled
Study of the Involvement of Fatty Acids in Retinopathy of Prematurity: Relationship Between Retinopathy of Prematurity and the Rate of Expression of Transplacental Fatty Acid Receptors.
Recruiting·—·N/A·NCT04819893·135 enrolled
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
Recruiting·AAsociación para Evitar la Ceguera en México·Phase 2/3·NCT00346814
Drug Utilization Study for Eylea 40 mg/mL Using the PICLEO Paediatric Dosing Device in Preterm Infants With Retinopathy of Prematurity in the UK
Recruiting·Bayer logoBayer·N/A·NCT06315556·200 enrolled
Special Drug Use Investigation for Eylea for Retinopathy of Prematurity (ROP)
Active, not recruiting·Bayer logoBayer·N/A·NCT05705258·75 enrolled
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Completed·Takeda logoTakeda·Phase 2·NCT01096784·121 enrolled
Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening
Completed·—·Phase 4·NCT05043077·83 enrolled
To Assess the Effect of Dexamethasone Eye Drops on the Retinopathy of Prematurity Outcome
Completed·—·N/A·NCT06775353·2,017 enrolled
Effect of Vitamin E for Prevention of Retinopathy of Prematurity: A Randomized Clinical Trial.
Completed·IInstituto Nacional de Perinatologia Isidro Espinosa de los Reyes·N/A·NCT03274596·90 enrolled
Pain Management During Screening for Retinopathy of Prematurity
Completed·IIstanbul Medeniyet University·N/A·NCT04767178·44 enrolled
umBilical Or Adult Donor Red Blood Cells in Extremely Low Gestational Age Neonates and Retinopathy of Prematurity (BORN)
Completed·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 2·NCT05100212·146 enrolled
Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
Completed·JJaeb Center for Health Research·Phase 1·NCT02390531·120 enrolled
Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
Completed·Regeneron logoRegeneron·Phase 3·NCT04101721·127 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)